Levodopa Benserazide Madopar — Competitive Intelligence Brief

Levodopa Benserazide Madopar (Levodopa Benserazide Madopar) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine precursor with peripheral decarboxylase inhibitor. Area: Neurology.

marketed Dopamine precursor with peripheral decarboxylase inhibitor Dopamine pathway; aromatic amino acid decarboxylase (inhibited by benserazide) Neurology Small molecule

Target snapshot

Levodopa Benserazide Madopar (Levodopa Benserazide Madopar) — IRCCS San Raffaele Roma. Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while benserazide inhibits peripheral conversion of levodopa to prevent side effects.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Levodopa Benserazide Madopar TARGET	Levodopa Benserazide Madopar	IRCCS San Raffaele Roma	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic amino acid decarboxylase (inhibited by benserazide)
controlled-release levodopa / carbidopa	controlled-release levodopa / carbidopa	Pfizer	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (AADC); dopamine pathway
Levodopa + benserazide	Levodopa + benserazide	University of Buenos Aires	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic L-amino acid decarboxylase (peripheral inhibition)
Levodopa / Carbidopa	Levodopa / Carbidopa	Ross D. Zafonte, MD	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (AADC); dopamine pathway
levodopa/dopa decarboxylase inhibitor	levodopa/dopa decarboxylase inhibitor	Bial - Portela C S.A.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (peripheral inhibition); dopamine receptors (central effect)
Levodopa Benserazide Teva Italia	Levodopa Benserazide Teva Italia	IRCCS San Raffaele Roma	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (inhibited by benserazide); dopamine receptors (target of levodopa-derived dopamine)
Levodopa and carbidopa	Levodopa and carbidopa	NeuroDerm Ltd.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic L-amino acid decarboxylase (inhibited by carbidopa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine precursor with peripheral decarboxylase inhibitor class)

1. Bial - Portela C S.A. · 2 drugs in this class
2. IRCCS San Raffaele Roma · 2 drugs in this class
3. NeuroDerm Ltd. · 1 drug in this class
4. Pfizer · 1 drug in this class
5. Ross D. Zafonte, MD · 1 drug in this class
6. University of Buenos Aires · 1 drug in this class
7. AbbVie · 1 drug in this class
8. XenoPort, Inc. · 1 drug in this class
9. Intec Pharma Ltd. · 1 drug in this class